Physician profile
Amer Sidani
NPI 1790948180
$17,580.16
in general payments reported to CMS, 2019-2025
69 companies · $8,857 in 2025
The $8,857 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $766 · 2021: $922 · 2022: $1,577 · 2023: $1,715 · 2024: $2,594 · 2025: $8,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,175 · Consulting Fee: $5,125 · Travel and Lodging: $609 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,174.77 |
| Consulting Fee | $5,125.00 |
| Travel and Lodging | $609.47 |
| Education | $257.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,492.68 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Astrazeneca Pharmaceuticals LP | $2,524.11 | 2019-2025 | Lynparza, Calquence, Imfinzi |
| Celgene Corporation | $666.29 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $604.01 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $542.08 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $483.25 | 2019-2023 | Kyprolis, Nplate, Xgeva |
| Glaxosmithkline, LLC. | $460.04 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Pfizer INC. | $431.54 | 2019-2025 | |
| Janssen Biotech, INC. | $428.88 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| Gilead Sciences, INC. | $318.91 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $318.55 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Eisai INC. | $313.82 | 2020-2025 | |
| Genzyme Corporation | $309.75 | 2019-2025 | |
| Genentech USA, INC. | $276.95 | 2019-2025 | Alecensa, Tecentriq Hybreza, Polivy |
| Abbvie INC. | $275.23 | 2021-2025 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Sidani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.